HALO vs. HIMS
Compare and contrast key facts about Halozyme Therapeutics, Inc. (HALO) and Hims & Hers Health, Inc. (HIMS).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: HALO or HIMS.
Correlation
The correlation between HALO and HIMS is 0.42, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.
Performance
HALO vs. HIMS - Performance Comparison
Key characteristics
HALO:
1.38
HIMS:
2.97
HALO:
2.14
HIMS:
3.01
HALO:
1.32
HIMS:
1.40
HALO:
1.94
HIMS:
5.41
HALO:
5.12
HIMS:
11.47
HALO:
12.84%
HIMS:
29.75%
HALO:
44.71%
HIMS:
110.12%
HALO:
-74.26%
HIMS:
-87.29%
HALO:
-3.44%
HIMS:
-25.23%
Fundamentals
HALO:
$7.56B
HIMS:
$9.13B
HALO:
$3.43
HIMS:
$0.53
HALO:
17.84
HIMS:
79.02
HALO:
-2.50
HIMS:
3.85
HALO:
7.38
HIMS:
6.18
HALO:
20.78
HIMS:
19.15
HALO:
$1.08B
HIMS:
$1.78B
HALO:
$887.05M
HIMS:
$1.33B
HALO:
$530.80M
HIMS:
$123.98M
Returns By Period
In the year-to-date period, HALO achieves a 41.66% return, which is significantly lower than HIMS's 112.57% return.
HALO
41.66%
17.71%
13.55%
61.22%
23.55%
16.03%
HIMS
112.57%
96.93%
117.61%
323.05%
38.95%
N/A
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
HALO vs. HIMS — Risk-Adjusted Performance Rank
HALO
HIMS
HALO vs. HIMS - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Halozyme Therapeutics, Inc. (HALO) and Hims & Hers Health, Inc. (HIMS). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Dividends
HALO vs. HIMS - Dividend Comparison
Neither HALO nor HIMS has paid dividends to shareholders.
Drawdowns
HALO vs. HIMS - Drawdown Comparison
The maximum HALO drawdown since its inception was -74.26%, smaller than the maximum HIMS drawdown of -87.29%. Use the drawdown chart below to compare losses from any high point for HALO and HIMS. For additional features, visit the drawdowns tool.
Volatility
HALO vs. HIMS - Volatility Comparison
The current volatility for Halozyme Therapeutics, Inc. (HALO) is 20.47%, while Hims & Hers Health, Inc. (HIMS) has a volatility of 35.92%. This indicates that HALO experiences smaller price fluctuations and is considered to be less risky than HIMS based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Financials
HALO vs. HIMS - Financials Comparison
This section allows you to compare key financial metrics between Halozyme Therapeutics, Inc. and Hims & Hers Health, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
HALO vs. HIMS - Profitability Comparison
HALO - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Halozyme Therapeutics, Inc. reported a gross profit of 216.46M and revenue of 264.86M. Therefore, the gross margin over that period was 81.7%.
HIMS - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Hims & Hers Health, Inc. reported a gross profit of 430.69M and revenue of 586.01M. Therefore, the gross margin over that period was 73.5%.
HALO - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Halozyme Therapeutics, Inc. reported an operating income of 141.54M and revenue of 264.86M, resulting in an operating margin of 53.4%.
HIMS - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Hims & Hers Health, Inc. reported an operating income of 57.90M and revenue of 586.01M, resulting in an operating margin of 9.9%.
HALO - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Halozyme Therapeutics, Inc. reported a net income of 118.10M and revenue of 264.86M, resulting in a net margin of 44.6%.
HIMS - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Hims & Hers Health, Inc. reported a net income of 49.49M and revenue of 586.01M, resulting in a net margin of 8.4%.